• Explore /
  • Poster
  • / Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.

Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.

Abstract Poster

Authors

null

Ann-Lii Cheng

Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan

Ann-Lii Cheng , Jinlin Hou , Weijia Fang , Zhiwei Li , Sheng Hu , Hongming Pan , Yajin Chen , Chiun Hsu , Yuxian Bai , Zhiqiang Meng , Ming-Mo Hou , Congying Xie , Yong Liu , John Wu , Bai Li , Sandra Chica-Duque , Zhenggang Ren

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03419897

DOI

10.1200/JCO.2022.40.4_suppl.411

Abstract #

411

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Julien Edeline

First Author: Julien Edeline

First Author: Ghassan K. Abou-Alfa

First Author: Daneng Li